ScriptPro to outfit NIH
MISSION, Kan. —Retail pharmacies aren’t the only ones embracing technology like pharmacy automation. The government is doing it, too.
ScriptPro said last month that it had received a contract to provide pharmacy automation systems to the National Institutes of Health in Bethesda, Md. The company said its robotic dispensing, pharmacy management and drug information systems would be implemented at the NIH to assist in internal control and identification of drugs, while enhancing the safety and efficiency of medication dispensing and use by patients, with a specific focus on take-home medication orders provided to day hospital and clinic patients.
In addition to the NIH, ScriptPro’s list of government customers now includes the Veterans Health Administration, the Food and Drug Administration and the Department of Defense. The company said in April that the U.S. Navy had adopted its telepharmacy services in order to make up for a shortage of pharmacists, allowing pharmacists to examine medications and counsel patients through a video and audio link.
‘Picture This’ forums bring diabetes management awareness to public
PRINCETON, N.J. A few days after it released a report on how awareness and education play an integral role in the prevention, detection and treatment of diabetes, Novo Nordisk is bringing it to the public.
The drug maker said Friday that, through its collaboration with the Entertainment Industries Council, it will host "Picture This" forums, which include an open discussion among diabetes stakeholders and the media to identify top diabetes communication challenges, explore strategies to address those priorities and strengthen community understanding about diabetes through news media and community affairs programs.
The forums will be held in Philadelphia on Oct. 22 and Seattle on Nov. 18.
"Novo Nordisk is proud to join EIC, the media and community leaders in Seattle and Philadelphia to explore ways to improve how diabetes is communicated about and understood by local citizens," said Tony Deluzio, senior medical director at Novo Nordisk. "As the prevalence of diabetes continues to be on the rise, bringing together those on the front line of diabetes care will open the potential to reduce the stigma associated with diabetes and empower those affected by the disease to lead full and productive lives."
Pfizer makes official tender offer for King
NEW YORK Pfizer officially has made its tender offer to buy King Pharmaceuticals for $3.6 billion, or $14.25 per share, Pfizer said Friday.
The offer constitutes a 40% premium over the closing price of King’s stock on Oct. 11, when Pfizer originally made the offer. King, based in Bristol, Tenn., specializes in pain medications designed to deter misuse and abuse, and Pfizer said the acquisition would enhance its position in the pain-relief market.
The offer expires at midnight on Nov. 19.